Modeling drug response using network-based personalized treatment prediction (NetPTP) with applications to inflammatory bowel disease
Fig 3
Principal components analysis showing drug responders and nonresponders before and after infliximab treatment in patients with CD (A) and UC (B) from GSE16879. Responder samples after treatment appear to migrate towards the control healthy samples.